• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Kezar Life Sciences Inc. (Amendment)

    2/13/24 11:55:21 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZR alert in real time by email
    SC 13G/A 1 d10963180_13g-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

     

    Kezar Life Sciences, Inc.
    (Name of Issuer)

     

     

     

    Common Stock, $0.001 par value
    (Title of Class of Securities)

     

     

     

    49372L100
    (CUSIP Number)

     

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     
    CUSIP No. 49372L100    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Suvretta Capital Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      7,167,591      
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      7,167,591      
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      7,167,591      
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IA, OO

     

     

     
     
     

     

    CUSIP No. 49372L100  

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Averill Master Fund, Ltd.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      6,752,287      
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      6,752,287      
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      6,752,287      
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.3%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

     

    CO

     

     

     
     

     

    CUSIP No. 49372L100    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Aaron Cowen  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      U.S.A.  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      7,167,591      
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      7,167,591      
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      7,167,591      
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IN, HC

     

     

     

     
     

     

    CUSIP No. 49372L100  

     

    Item 1. (a). Name of Issuer:
         
        Kezar Life Sciences, Inc.
         
      (b). Address of Issuer's Principal Executive Offices:
         
       

    4000 Shoreline Court, Suite 300

    South San Francisco, CA, 94080

     

    Item 2.    
         
      (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing:
         
       

    Suvretta Capital Management, LLC – Delaware

    Averill Master Fund, Ltd. – Cayman Islands

       

    Aaron Cowen – U.S.A. 

         
       

    Suvretta Capital Management, LLC:

    540 Madison Avenue, 7th Floor

    New York, New York 10022

       

    United States of America

     

    Averill Master Fund, Ltd.:

    c/o Maples Corporate Services Limited

    P.O. Box 309

    Ugland House

    Grand Cayman KY1-1104

    Cayman Islands

     

    Aaron Cowen:

    c/o Suvretta Capital Management, LLC

    540 Madison Avenue, 7th Floor

    New York, New York 10022

         
      (d).   Title of Class of Securities:
         
        Common Stock, $0.001 par value (the “Common Stock”)
         
      (e). CUSIP Number:
         
        49372L100
         
     
     

     

    Item 3.   If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
    Item 4. Ownership.
     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

      (a)   Amount beneficially owned:
         
        Suvretta Capital Management, LLC – 7,167,591    
        Averill Master Fund, Ltd. – 6,752,287    
        Aaron Cowen – 7,167,591    
         
      (b)   Percent of class:
         
        Suvretta Capital Management, LLC – 9.9%
        Averill Master Fund, Ltd. – 9.3%
        Aaron Cowen – 9.9%

     

     

       
      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (ii)   Shared power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 7,167,591    
          Averill Master Fund, Ltd. – 6,752,287    
          Aaron Cowen – 7,167,591    
             
        (iii) Sole power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (iv)   Shared power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 7,167,591    
          Averill Master Fund, Ltd. – 6,752,287    
          Aaron Cowen – 7,167,591    

     

     
     

     

     
    Item 5. Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
     
      N/A
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      N/A  
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
      See Exhibit B attached hereto.
       
       
    Item 8. Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
      N/A
       
       
    Item 9. Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     
      N/A
       
       
    Item 10. Certification.
     
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 13, 2024
      (Date)
       
      Suvretta Capital Management, LLC*
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.*

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen*

     

      /s/ Aaron Cowen
      (Signature)
       
       

    *Each Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     
     

     

    Exhibit A

     

    AGREEMENT

     

    The undersigned agree that this Amendment 2 to Schedule 13G dated February 13, 2024 relating to the Common Stock, $0.001 par value of Kezar Life Sciences, Inc. shall be filed on behalf of the undersigned.

      February 13, 2024
      (Date)
       
      Suvretta Capital Management, LLC
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen

     

      /s/ Aaron Cowen
      (Signature)
       
       

     

     
     

     

    Exhibit B

     

    Aaron Cowen has beneficial ownership by virtue of his role as a control person of Suvretta Capital Management, LLC.

     

     

     

     

     

     

    Get the next $KZR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KZR

    DatePrice TargetRatingAnalyst
    8/11/2023$4.00Overweight → Equal Weight
    Wells Fargo
    3/16/2023Outperform → Mkt Perform
    William Blair
    12/8/2021$19.00Overweight
    Wells Fargo
    11/16/2021$12.00 → $20.00Buy
    HC Wainwright & Co.
    7/20/2021$14.00Buy
    JonesTrading
    More analyst ratings

    $KZR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

      Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared

      3/25/25 7:30:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET. The event will highlight topline data from Kezar's PORTOLA trial, a placebo-controlled, randomized, double-blind Phase 2a clinical trial evaluating the efficacy and safety of zetomipzomib in patients with AIH. Additionally, the event will feature presentations from Craig Lammert, MD, Associate Professor of

      3/24/25 8:00:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present at a virtual Key Opinion Leader (KOL) event hosted by William Blair on zetomipzomib clinical development in autoimmune hepatitis (AIH) and will also provide a safety update from the PALIZADE Phase 2b clinical trial in patients with active lupus nephritis (LN) on Thursday, February 27, 2025, at 4:00 p.m. ET. The event will feature Aparna Goel, MD, a general transplant and hepatologist at Stanford University, who will discuss the burden of autoimmune hepatitis (AIH) on patients, curre

      2/18/25 4:01:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Leadership Updates

    Live Leadership Updates

    See more
    • Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

      Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026 Co-Founder and Board Director, Christopher Kirk, PhD, appointed as Chief Executive Officer   Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment

      10/3/23 4:10:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

      Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritis Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer Cash, cash equivalents and marketable securities totaled $306.8 million as of June 30, 2022 Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. "The second quarter was tremendously productive for Kezar, during which we achieved key clinical milestone

      8/11/22 4:01:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      Kezar Life Sciences, Inc., (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that, in connection with the previously announced appointment of Nick Mordwinkin, Pharm.D., Ph.D., as the Company's Chief Business Officer, the Compensation Committee of the company's Board of Directors granted Dr. Mordwinkin a nonqualified stock option to purchase 200,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar's common stock on August 1, 2022. In addition, the Compensation Committee of the company's Board of Directors granted

      8/3/22 4:30:00 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Chiang Pichi Luo claimed ownership of 2,975 shares (SEC Form 3)

      3 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

      4/16/25 4:41:19 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider To Zung Phoung

      3 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

      4/16/25 4:39:49 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Legal Officer Schiller Mark C.

      4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)

      4/1/25 8:42:03 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Kezar Life Sciences Inc.

      DEFA14A - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/25/25 4:12:43 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Kezar Life Sciences Inc.

      DEF 14A - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/25/25 4:10:58 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)

      4/1/25 4:05:51 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Kezar Life Sciences Inc.

      SC 13D - Kezar Life Sciences, Inc. (0001645666) (Subject)

      10/8/24 4:20:17 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kezar Life Sciences Inc.

      SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

      7/8/24 4:32:39 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kezar Life Sciences Inc. (Amendment)

      SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)

      2/14/24 6:47:29 PM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kezar Life Sciences downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00

      8/11/23 7:45:02 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences downgraded by William Blair

      William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform

      3/16/23 7:29:33 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Kezar Life Sciences with a new price target

      Wells Fargo initiated coverage of Kezar Life Sciences with a rating of Overweight and set a new price target of $19.00

      12/8/21 7:24:52 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KZR
    Financials

    Live finance-specific insights

    See more
    • Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

      Company-hosted conference call and webcast to be held today at 8:00 a.m. ET Zetomipzomib treatment results in steroid-sparing biochemical remissions in accordance with AASLD treatment guidelines in a difficult-to-treat, refractory AIH patient population. In relapsed, steroid-dependent AIH patients, of the 21 of 24 entering screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less, compared to 0 of 7 of placebo patients. In the intention-to-treat (ITT) population, 31% (5 of 16) of zetomipzomib patients achieved a CR and steroid taper (≤5 mg/day), compared

      3/25/25 7:30:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the "Board") has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the outstanding shares of common stock of Kezar for cash consideration of $1.10 per share, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of Kezar's development programs or intellectual property. After careful consideration and with the a

      10/17/24 8:35:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

      Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT. "The goal of Kezar's R&D Day is to set expectations for 2023, provide updates on our two clinical assets, and highlight the productivity from our Discovery team. We are progressing more quickly than planned with initiating PALIZADE, our next study of zetomipzomib for the treatment of lupus nephritis, and look forward to sharing the details," said John Fowler, Kezar's

      3/13/23 7:00:00 AM ET
      $KZR
      Biotechnology: Pharmaceutical Preparations
      Health Care